Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2018 09:05 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association

- 16/17 (94%) Responding RET-Mutant Medullary Thyroid Cancer Patients Remain on Therapy, With Median Follow-Up of 8.4 Months - - 7/7 (100%) Responding RET Fusion-Positive Thyroid Cancer Patients...
September 25, 2018 16:20 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung Cancer

- 25/26 (96%) Responding Patients Remain on Therapy, With Median Follow-Up of 9.5 Months - STAMFORD, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a...
September 18, 2018 06:45 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Announces Accepted Abstracts at the 88th Annual Meeting of the American Thyroid Association

STAMFORD, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined...
September 05, 2018 06:45 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292

STAMFORD, Conn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined...
August 29, 2018 06:45 ET | Source: Loxo Oncology, Inc.

Loxo Oncology to Present at Upcoming Investor Conferences

STAMFORD, Conn., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
August 27, 2018 02:30 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Announces Submission of European Marketing Authorization Application for Larotrectinib

STAMFORD, Conn., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
August 10, 2018 16:30 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Announces Accepted Abstracts at the IASLC 19th World Conference on Lung Cancer

STAMFORD, Conn., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
August 09, 2018 06:45 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Reports Second Quarter 2018 Financial Results

- LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 - - Updated Larotrectinib Duration of Response Data to be Reported at ESMO - - Larotrectinib NDA PDUFA date is November...
August 02, 2018 06:45 ET | Source: Loxo Oncology, Inc.

Loxo Oncology to Announce Second Quarter 2018 Financial Results

STAMFORD, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
June 02, 2018 09:00 ET | Source: Loxo Oncology, Inc.

Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting

– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) – – Activity Observed Independent of RET Alteration, Tumor Type...